Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing.
Shafer P, Leung WK, Woods M, Choi JM, Rodriguez-Plata CM, Maknojia A, Mosquera A, Somes LK, Joubert J, Manliguez A, Ranjan R, Burt B, Lee HS, Zhang B, Fuqua S, Rooney C, Leen AM, Hoyos V. Shafer P, et al. Among authors: hoyos v. Cytotherapy. 2024 Mar;26(3):266-275. doi: 10.1016/j.jcyt.2023.12.002. Epub 2024 Jan 15. Cytotherapy. 2024. PMID: 38231165 Free article.
Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer.
Hoyos V, Vasileiou S, Kuvalekar M, Watanabe A, Tzannou I, Velazquez Y, French-Kim M, Leung W, Lulla S, Robertson C, Foreman C, Wang T, Bulsara S, Lapteva N, Grilley B, Ellis M, Osborne CK, Coscio A, Nangia J, Heslop HE, Rooney CM, Vera JF, Lulla P, Rimawi M, Leen AM. Hoyos V, et al. Ther Adv Med Oncol. 2022 Jul 15;14:17588359221107113. doi: 10.1177/17588359221107113. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35860837 Free PMC article.
Targeting IDH2R140Q and other neoantigens in acute myeloid leukemia.
Leung WK, Torres Chavez AG, French-Kim M, Shafer P, Mamonkin M, Hill LC, Kuvalekar M, Velazquez Y, Watanabe A, Watanabe N, Hoyos V, Lulla P, Leen AM. Leung WK, et al. Among authors: hoyos v. Blood. 2024 Apr 25;143(17):1726-1737. doi: 10.1182/blood.2023021979. Blood. 2024. PMID: 38241630
Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer.
Nalawade SA, Shafer P, Bajgain P, McKenna MK, Ali A, Kelly L, Joubert J, Gottschalk S, Watanabe N, Leen A, Parihar R, Vera Valdes JF, Hoyos V. Nalawade SA, et al. Among authors: hoyos v. J Immunother Cancer. 2021 Nov;9(11):e003237. doi: 10.1136/jitc-2021-003237. J Immunother Cancer. 2021. PMID: 34815355 Free PMC article.
High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.
Quintarelli C, Dotti G, Hasan ST, De Angelis B, Hoyos V, Errichiello S, Mims M, Luciano L, Shafer J, Leen AM, Heslop HE, Rooney CM, Pane F, Brenner MK, Savoldo B. Quintarelli C, et al. Among authors: hoyos v. Blood. 2011 Mar 24;117(12):3353-62. doi: 10.1182/blood-2010-08-300376. Epub 2011 Jan 28. Blood. 2011. PMID: 21278353 Free PMC article.
37 results